New NASH drug J2H-1702 begins human safety testing
NCT ID NCT06308861
First seen Jan 11, 2026 · Last updated May 08, 2026 · Updated 17 times
Summary
This early-stage trial tested the safety and tolerability of a new drug called J2H-1702 in 100 healthy men. The drug is being developed for non-alcoholic steatohepatitis (NASH), a serious liver condition. Researchers gave single and multiple doses to see how the body processes the drug and if it causes side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-ALCOHOLIC STEATOHEPATITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
J2H Biotech
Suwon, Gyeonggi-do, 16684, South Korea
Conditions
Explore the condition pages connected to this study.